Shanghai Labway Clinical Laboratory Co., Ltd.

Shenzhen Stock Exchange 301060.SZ

Shanghai Labway Clinical Laboratory Co., Ltd. Revenue for the year ending December 31, 2023: USD 235.83 M

Shanghai Labway Clinical Laboratory Co., Ltd. Revenue is USD 235.83 M for the year ending December 31, 2023, a -61.24% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.

Shanghai Labway Clinical Laboratory Co., Ltd. Revenue for the year ending December 31, 2022 was USD 608.52 M, a 117.43% change year over year.
Shanghai Labway Clinical Laboratory Co., Ltd. Revenue for the year ending December 31, 2021 was USD 279.87 M, a 47.54% change year over year.
Shanghai Labway Clinical Laboratory Co., Ltd. Revenue for the year ending December 31, 2020 was USD 189.69 M, a 14.52% change year over year.
Shanghai Labway Clinical Laboratory Co., Ltd. Revenue for the year ending December 31, 2019 was USD 165.64 M, a 8.22% change year over year.

Key data

Date	Revenue	Gross Profit	Operating Income	EBIT

Shenzhen Stock Exchange: 301060.SZ

Shanghai Labway Clinical Laboratory Co., Ltd.

CEO	Mr. Weixiong Zeng
IPO Date	Sept. 13, 2021
Location	China
Headquarters	Building 1, Lane 268
Employees	1,487
Sector	Healthcare
Industries Biotechnology Cleaning Supplies Cosmetics Drugstores & Retail Pharmacies Hardware & Electronics Personal Care Professional Services Specialty Retail

Description

Shanghai Labway Clinical Laboratory Co., Ltd. offers sales services for in vitro diagnostic products; and medical laboratory services. Shanghai Labway Clinical Laboratory Co., Ltd. was founded in 1993 and is based in Shanghai, China.

Key trends

Past 5 years